Official Website of the EANM Annual Congress 2025. Get all your information here. Abstract submission is now open!

Special Track Session 2 Sunday, October 5, 2025 | 09:45 - 11:15 | EANM Arena (Room 112) Oncology & Theranostics Committee | Debate: A Brave New World: Are All PSMA Radiopharmaceuticals Equal?

Debate: A Brave New World: Are All PSMA Radiopharmaceuticals Equal? 303 Learn & Improve Professional Skills 10:00– (LIPS) Track Bone & Joint Committee Bone and Joint Therapies 304 M2M Track TROP / Featured Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee TBA 305 Cutting Edge Science Track Featured ...

2024年10月28日 · The European Association of Nuclear Medicine (EANM) hosted its annual conference, EANM24, from October 19-22, 2024, in Hamburg, Germany. EANM conferences are known for showcasing advancements in nuclear medicine, which can be broadly categorized into key areas: New Targets: Identification of novel proteins and enzymes in different cancers and ...

2025年1月30日 · Controversy: Is it Time to Include PET Tracers other than FDG in Systemic Staging & Therapy Selection? Chairpersons: Nadia Harbeck, Gary Cook, Pascal Baltzer. Controversy: Is FDG PET/CT Ready to Assess Therapy Response? Chairpersons: Carolien Schröder, Malene Gubbe Hildebrandt, Ritse Mann.

The EANM Annual Congress draws over 8,700 participants from across Europe and many other countries, creating a vibrant and diverse international gathering.

2025 EANM Young Investigators Meeting (YIM’25) For this year’s edition of the YIM, join us in exploring the cutting edge of Artificial Intelligence (AI) applications in nuclear medicine with the theme: ‘From Bytes to Bedside: Clinical AI, You, and the Future of Nuclear Medicine’.

The second day starts with a group debate about hurdles and barriers that participants encounter in their early careers. This debate is followed by a workshop on delivering powerful elevator pitches. Finally, a presentation on how to get published in high-impact journals concludes the …

• In a prospective trial of DCFPyLin 184 patients with initially diagnosed and recurrent prostate cancer, 50 of 60 (83%) biopsied DCFPyL-avid lesions were malignant at biopsy.

Welcome Words by the Chair of the EANM Technologists Committee. General Information Dates and Deadlines General Information Congress Venue FAQs Congress App Useful Contacts EANM'25 Code of Conduct Sustainability EANM'25 …